Evidence map›Paper›PMID 35860236›Full record

ArticleFrontiers in immunology2022

Rebeca Viurcos-Sanabria, Aarón N Manjarrez-Reyna, Helena Solleiro-Villavicencio, Salma A Rizo-Téllez, Lucía A Méndez-García, Victoria Viurcos-Sanabria, Jacquelina González-Sanabria, América Arroyo-Valerio, José D Carrillo-Ruíz, Antonio González-Chávez and 4 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Rebeca Viurcos-SanabriaLaboratory of Immunometabolism, Research Division, General Hospital of Mexico "Dr. Eduardo Liceaga", Mexico City, Mexico.
Aarón N Manjarrez-ReynaLaboratory of Immunometabolism, Research Division, General Hospital of Mexico "Dr. Eduardo Liceaga", Mexico City, Mexico.
Helena Solleiro-VillavicencioPosgrado de Ciencias Genómicas, Universidad Autónoma de la Ciudad de México, Mexico City, Mexico.
Salma A Rizo-TéllezLaboratory of Immunometabolism, Research Division, General Hospital of Mexico "Dr. Eduardo Liceaga", Mexico City, Mexico.
Lucía A Méndez-GarcíaLaboratory of Immunometabolism, Research Division, General Hospital of Mexico "Dr. Eduardo Liceaga", Mexico City, Mexico.
Victoria Viurcos-SanabriaLaboratory of Immunometabolism, Research Division, General Hospital of Mexico "Dr. Eduardo Liceaga", Mexico City, Mexico.
Jacquelina González-SanabriaLaboratory of Immunometabolism, Research Division, General Hospital of Mexico "Dr. Eduardo Liceaga", Mexico City, Mexico.
América Arroyo-ValerioResearch Directorate, General Hospital of Mexico "Dr. Eduardo Liceaga", Mexico City, Mexico.
José D Carrillo-RuízResearch Directorate, General Hospital of Mexico "Dr. Eduardo Liceaga", Mexico City, Mexico.
Antonio González-ChávezClínica de Atención Integral para Pacientes con Diabetes y Obesidad, General Hospital of Mexico "Dr. Eduardo Liceaga", Mexico City, Mexico.
Jose I León-PedrozaFaculty of Health Sciences, Anahuac University, Mexico City, Mexico.
Raúl Flores-MejíaLaboratorio 103, Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Díaz Mirón, Casco de Santo Tomas, Ciudad de México, Mexico.
Octavio Rodríguez-CortésLaboratorio 103, Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Díaz Mirón, Casco de Santo Tomas, Ciudad de México, Mexico.
Galileo EscobedoLaboratory of Immunometabolism, Research Division, General Hospital of Mexico "Dr. Eduardo Liceaga", Mexico City, Mexico.
Hospital General de México · MXInstituto Politécnico Nacional · MXUniversidad Anáhuac · MXUniversidad Autónoma de la Ciudad de México · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The contribution of the cellular immune response to the severity of coronavirus disease 2019 (COVID-19) is still uncertain because most evidence comes from patients receiving multiple drugs able to change immune function. Herein, we conducted a prospective cohort study and obtained blood samples from 128 unvaccinated healthy volunteers to examine the

Indexed as

COVID-19HumansImmunity, CellularInterleukin-2MonocytesProgrammed Cell Death 1 ReceptorProspective StudiesRetrospective StudiesSARS-CoV-2T-LymphocytesInterleukin-2Programmed Cell Death 1 ReceptorCOVID-19IFN-alphaIFN-gammaIL-2monocytePD-1SARS-CoV-2T cell

Identifiers

PMID35860236
PMCPMC9289744
OpenAlexW4283793223

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.